Home > Insider Trading > Filing (0000950170-24-070875)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1819133	Tango Therapeutics Inc.	TNGX	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1730866	Ann Lesley Calhoun	C/O Tango Therapeutics, Inc 201 Brookline Ave., Suite 901 Boston MA 02215		No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-06-05	6,250	$0.00	11,250	No	4	A	Direct
Common Stock	Acquisiton	2024-06-05	5,000	$7.21	6,250	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	A	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (Right to Buy)	Acquisiton	2024-06-05	37,500	$0.00	37,500	$7.41

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
37,500		2034-06-05	No	4	A	Direct

Footnotes

These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in its entirety on the earlier of: (i) June 5, 2025 and (iii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.
The reported sale occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2023.
Represents the weighted average sales price per share. The shares sold at prices ranging from $7.01 to $7.38 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.
This option shall vest and become exercisable in 12 substantially equal monthly installments over a period of one year beginning on July 5, 2024, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date.